INTRODUCTION
Acute myeloid leukemia (AML) is characterized by an accumulation of blast cells, an increase in the self-renewal capacity of leukemic stem cells and a block in the differentiation of myeloid blasts. 1 AML is frequently associated with specific chromosomal translocations, such as t(15;17), t(6;9), inv (16) and t (8;21) . 2 Acute promyelocytic leukemia (APL), a subtype of AML, harbors the t(15;17) translocation in about 95% of cases; this translocation encodes the promyelocytic leukemia/retinoic acid receptor alpha (PML/RARa) fusion protein. A smaller percentage (less than 2%) of APL patients harbor the t(11;17) translocation encoding the promyelocytic leukemia zinc finger/RARa (PLZF/RARa) fusion protein. 3 Both of the APL-associated fusion proteins, PML/RARa and PLZF/RARa (X-RARa), are oncogenic transcription factors that are capable of inducing leukemia in vivo.
4 --6 X-RARa proteins, the t(8;21)-associated AML-1/ETO fusion protein and other fusion proteins interfere with myeloid differentiation through several different mechanisms that all lead to the silencing of genes indispensable for normal differentiation. 7, 8 These mechanisms include the aberrant recruitment of histone deacetylase activity, the sequestration of key differentiation factors, the de-regulation of co-activator binding 9 and the inhibition of differentiationassociated transcription factors by direct binding, which can lead to their de-localization. 10 The differentiation of hematopoietic stem cells (HSCs) into various myeloid lineages is controlled by the functional balance between three transcription factors: PU.1, C/EBPa and GATA-1.
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PU.1, a member of the E-twenty-six family of transcription factors, is essential for normal hematopoiesis and has a critical role in lineage commitment and HSC maintenance. PU.1 is expressed in HSCs, common myeloid progenitors and common lymphoid progenitors. 12, 13 Disruption of the PU.1 gene leads to (i) defective stem-cell function, 14, 15 (ii) a block in the differentiation of HSCs to common myeloid progenitors and common lymphoid progenitors 12 and (iii) impaired myeloid and B-cell development. 14, 15 The crucial role of the PU.1 expression level is demonstrated by the observation that the disruption of PU.1 or the gradual reduction in PU.1 expression induces a leukemic phenotype in mice. 16, 17 The ability of C/EBPa to induce differentiation also depends on the presence of PU.1. 18 Unmutated PML can associate with PU.1 during transcription and differentiation by its association with p300; however, the PML/RARa fusion protein, which functions as a dominant-negative PML, dissociates the PU.1/PML/ p300 protein complex and inhibits PU.1-induced transcription. 19 Taking these data into account, we investigated the mechanisms by which X-RARa proteins may interfere with the normal function of PU.1 and whether re-establishment of normal PU.1 function antagonises the leukemogenicity of X-RARa proteins.
MATERIALS AND METHODS Plasmids
The pE-PML/RARa and pE-PLZF/RARa plasmids for the Gateway insertion of the fusion proteins were described previously. 20, 21 The cDNAs encoding PML, PLZF, PML/RARa, PLZF/RARa, PU.1 and GFP were generated in previous studies. 20 --24 For further sub-cloning of the cDNAs into different expression vectors, the Gateway recombination system (Invitrogen, Darmstadt, Germany) was used. All cDNA sequences were cloned into the vector pENTR1A and shuttled with the 'LR-clonase' enzyme kit (Invitrogen) into plasmids previously converted to Gateway destination vectors according to the manufacturer's instructions. For retroviral transduction, we used the retroviral vector PINCO 25 and its derivative PAULO and PIDE. 26 For the mammalian two-hybrid analyses, we used the pBind, pAct and pSG5-luc vectors from Promega (Mannheim, Germany). The vectors containing a luciferase reporter construct under the control of the M-CSFR promoter (pGL3-c-fms) were generously provided by Marion Flick (Yale University, School of Medicine, New Haven, CT, USA). The pGL3-c-fms DPU.1 was generated by deletion of the PU.1-binding site using the following primers: 5 0 -ATCCTCGAGCGAGCAGGCTTTTCTGGCTC-3 0 and 5 0 -G AGGAATTCCTTCTCTCTTCTCCACCTTCTCC-3 0 . The pGL3-IL18 plasmid was previously described. 23 The pGL3-IL18DPU.1 was generated by sitedirected mutagenesis using the following primers: 5 0 -CCCTCCACCTT CTCTCTCATTCTCTC-3 0 and 5 0 -GAGAGAATGAGAGAGAAGGTGGAGGG-3 0 .
Cell lines, cell culture and western blotting HL60, NB4 and U937 cells were obtained from DSMZ (Braunschweig, Germany). The U937 cell lines B412 (PLZF/RARa-positive), PR9 (PML/RARapositive) and A/E (HA-AML-1/ETO-positive) have been extensively described elsewhere. 27, 28 These cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (Invitrogen, Darmstadt, Germany). The 293 cells (obtained from DSMZ) and the ecotropic packaging Phoenix cell line were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Invitrogen, Darmstadt, Germany).
Western blot analyses were performed using anti-RARa (C-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-HA (HA.11, PRB, Covance, Princeton, NJ, USA), anti-PU.1 (T-21; Santa Cruz Biotechnology), antiphospho-serine (p-Ser) (Sigma, Munich, Germany), anti-GFP (B2; Santa Cruz Biotechnology), anti-VP16 (14-5, Santa Cruz Biotechnology) and anti-atubulin (Neolab, Heidelberg, Germany) antibodies. Blocking was performed in 5% low-fat dry milk and washed in TBS/0.1% Tween 20. Antibodies were diluted in either 5% low-fat dry milk (anti-RARa, anti-VP16, anti-p-Ser) or Tween 20 (anti-HA, anti-PU.1, anti-GFP). Horseradish peroxidaseconjugated secondary antibodies (Dianova, Hamburg, Germany) were diluted in 5% low-fat dry milk.
Cell lysates were prepared in either SDS-lysis buffer (1.5 M Tris-HCl, pH 6.8, 20% SDS and 10% glycerol) or E1A buffer (150 mM NaCl, 50 mM HEPES, 50 mM Tris-HCl, pH 8.0, 50 mM HEPES, 0.1% NP40 and Roche protease inhibitors). For matrix association protocols, the pellet fraction (NP-40-insoluble fraction) was resuspended in LDS loading buffer (Invitrogen, Germany).
Immunofluorescence After 6 h induction with 100 mM Zn 2 SO 4 , U937 cells were treated with 1 mM ATRA or EtOH for 24 h.
Cells were applied to slides by cyto-centrifugation, fixed and permeabilized with paraformaldehyde (10 min at RT) and 0.1 % Triton (5 min at RT). The polyclonal rabbit anti-PU.1 antibody (sc-352 Santa Cruz Biotechnologies Inc.) and the monoclonal mouse anti-PML (sc-966, Santa Cruz Biotechnologies Inc.) and mouse anti-PLZF (OP128, Merck/ Calbiochem, Darmstadt, Germany) were diluted 1:300 in PBS supplemented with 0.1% bovine serum albumin (BSA, Sigma) and incubated with the cells over night at 4 1C. Cells were washed with PBS and incubated for at least 1 h with the secondary goat anti-mouse Alexa Fluor 488-conjugated antibody, the anti-rabbit Alexa Fluor 647-conjugated antibody (Invitrogen, Paisley, Scotland) (diluted 1:1000 in PBS supplemented with 0,1% BSA) and Hoechst33342 (1:2500, ABD-17533, Biomol, Hamburg, Germany). The cells were then washed with PBS and H 2 O before the coverslips were mounted with Mowiol (Sigma). NIH3T3 cells were infected with PIDE-and PAULObased retrovirus produced in phoenix cells. After HL60 and U937 cells were differentiated after induction with 1a,25-dihydroxy vitamin D 3 (Sigma) and transforming growth factor beta (TGF-b) as previously described. 28 After 5 days of treatment, the percentage of CD14-positive cells was evaluated using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA) and anti-CD14 antibody (BD Bioscience, Heidelberg, Germany). In each sample, viable cells were gated and the expression of surface markers was evaluated on 5 Â 10 3 cells.
Reporter assays U937-wt, U937-P/R9, U937-B412 and U937-A/E cells were treated with Zn 2 S0 4 (100 mM Sigma) 6 h before transfection to induce transgene expression. The pRL-CMV plasmid, which expresses renilla luciferase under the control of a CMV promoter, was cotransfected with pGL3-c-fms or pGL3-basic into U937-wt, U937-P/R9, U937-B412 and U937-A/E cells by 'nucleofection' (Lonza, Cologne, Switzerland) according to the manufacturer's instructions. Twenty-four hours after transfection, the luciferase activity of the cell lysate was determined using the 'Dual-Luciferase Reporter Assay System' (Promega, Madison, WI, USA) according to the manufacturer's instructions. The intensity of firefly luciferase was normalized to the intensity of renilla luciferase as a transfection control.
Mammalian two-hybrid
As 'bait,' we used the pBind-PU.1 vector, which encodes renilla luciferase and a fusion between GAL4 and PU.1 under the control of the SV40 promoter (Promega). The pAct vector, in which the VP16 sequence was fused to PML, PLZF, RARa, PML/RARa or PLZF/RARa, served as the 'prey' vector. One microgram of these vectors was cotransfected into 293 cells, together with 1 mg of the pG5luc vector containing the luciferase reporter under the control of five GAL4-responsive elements (Promega). Transfections were performed in triplicate using the calcium-phosphate precipitation method according to widely established procedures. Luciferase activity was detected using the 'Dual-Luciferase Reporter Assay System' (Promega) according to the manufacturer's instructions and normalized to renilla luciferase to control for transfection efficiency.
Immunoprecipitation
Phoenix cells were transfected with pCDNA3-empty, pCDNA3-PU.1, pCDNA3-PML/RARa and pCDNA3-PLZF/RARa alone or in combination; after 48 h from transfection, cells were lysed in a buffer containing 150 mM NaCl, 50 mM Tris-Cl, 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS and protease inhibitors (Roche Complete, Basel, Switzerland). Lysates were precleared for 1 h at 4 1C on Protein-G Sepharose (GE-Healthcare, Upsala, Sweden), and PU.1 was precipitated with an anti-PU.1 antibody overnight at 4 1C. Immunocomplexes were recovered with Protein-G Sepharose for 2 h at 4 1C. The beads were subsequently washed in the buffer described above and resuspended in SDS loading buffer containing a reducing agent. Five percent of the input served as a control. Samples were analyzed by western blot analysis. Anti-PU.1 and anti-RARa antibodies were used to detect the respective proteins.
Chromatin immunoprecipitation (ChIP) assay
Transgene expression was induced by treating the B412, P/R9 and A/E-U937 cells with 100 mM Zn 2 S0 4 for 8 h. Mock-transfected U937 cells served as a control. Crosslinking was performed with formaldehyde (1% final concentration) and terminated with glycine. Lysis was performed in a buffer containing both protease and phosphatase inhibitors (Calbiochem) and 400 ml glass beads (400 --600 m; Sigma). 0 for the amplification of the PDK4 promoter region as a control targeting an irrelevant promoter region. For the quantitative real-time PCR, we used the absolute qPCR Mix with SYBR GREEN (Thermo Scientific, Germany). The PCR for each sample was conducted in triplicate. One percent input was used as a reference. We analyzed the results using the DDCt-method to determine the portion of the precipitated DNA relative to the DNA amount used for the ChIP. To visualise protein, crosslinks were reversed at 65 1C overnight (in samples of 50 mg of input and 2% of the immunoprecipitated), and samples were analyzed by western blot analysis with anti-PU.1 antibodies.
Quantitative real-time PCR
Total RNA and first-strand cDNA were obtained from Sca1 þ /Lin À HSCs according to standard protocols. TaqMan PCR was conducted in duplicate following standard protocols using an ABI PRISM 7700 (Applied Biosystems, Darmstadt, Germany). To quantify PU.1 mRNA expression, the 'Assay-on-Demand' system was used according to the manufacturer's instructions (Applied Biosystems). Each sample was normalized to the level of expression of glyceraldehyde-3-phosphate dehydrogenase. The CT values were exported into a Microsoft Excel worksheet to calculate fold changes using the comparative CT method. The fold induction of targets after normalization to endogenous glyceraldehyde-3-phosphate dehydrogenase expression is presented as the 2 ÀDDCT value.
Isolation of murine Sca1 þ /lin À HSCs and retroviral infection
The isolation of Sca1 þ /lin À murine HSCs and retroviral infections were performed as previously described. 21 Infections were repeated in three alternating rounds for each construct, and doubly-infected cells were assessed by the detection of GFP and DNGFR using a PE-conjugated anti-NGFR antibody (Pharmingen, Heidelberg, Germany) as previously described. 30 
G/GM-CSF induced differentiation of murine HSCs Sca1
þ /lin À -cells were cultivated in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, mIL-3 (20 ng/ml), mIL-6 (20 ng/ml) and mSCF (100 ng/ml) (StemCell Technologies, Vancouver, BC, Canada) with or without G-CSF (60 ng/ml) and GM-CSF (20 ng/ml). On day 7 of cultivation, the cells were washed, and differentiation was assessed by FACS to determine the expression of Mac-1 and Gr-1 surface markers (Pharmingen, BD Biosciences, Germany). A total of 100 000 cells were spun in a cytofuge and stained with Wright/Giemsa solution to morphologically analyze their differentiation states. Protein lysates were prepared in SDS lysis buffer (50 mM Tris-Cl, pH 6.8, 2% SDS, 10% glycerol) and analyzed by western blotting with anti-RARa-and anti-PU.1 antibodies to detect the presence of the transgenes.
RESULTS
Both PML/RARa and PLZF/RARa interact with PU.1 APL is associated with a differentiation block caused by the oncogenic X-RARa transcription factors. Myeloid differentiation is mainly regulated by the key transcription factor PU.1, which can be functionally inhibited by interaction with the oncogenic fusion protein AML1/ETO. 9 To investigate whether X-RARa proteins also inhibit PU.1 function through direct interaction, we studied the interaction of these proteins with PU.1 in vivo. To accomplish this, we performed a mammalian two-hybrid experiment in human cells in which we co-expressed a GAL4-PU.1 fusion protein as bait and VP16-fusions of PML/RARa and PLZF/RARa as prey. The unmutated translocation partners RARa, PML and PLZF were used as control. We found that both PLZF and PLZF/RARa strongly interacted with PU.1, whereas PU.1 bound RARa and PML/RARa to a lesser extent (Figure 1a) , confirming previous reports of direct interaction of PU.1 and PML/RARa. 29 The expression levels of the transgenes were determined by western blot analysis (Figure 1b) . In this blot all expected proteins are shown; the VP16 peptide alone, with a molecular weight o10 kDa, was too small to be detected in this gel.
To confirm these results, we also performed a co-immunoprecipitation experiment and observed that both X-RARa fusion proteins co-immunoprecipitated with PU.1 (Figure 1c) . These data clearly show that both X-RARa proteins bind to PU.1.
Furthermore we co-expressed PU.1 fused to SNAP and X-RARa in NIH-3T3 murine cell and showed that in these cells the proteins co-localize into the nucleus as shown by a yellow coloration in the merged images (Figure 1d ).
The expression of PML/RARa or PLZF/RARa leads to a characteristic 'microspeckled' localization pattern of the fusion proteins. 24,31 --33 The direct interaction of PU.1 with X-RARa, as well as with PML and PLZF, raises the question whether the expression of PML/RARa or PLZF/RARa leads to a de-localization of PU.1 into these 'microspeckles.' Therefore, we studied the influence of X-RARa protein expression on the localization of PU.1 by indirect immunofluorescence. PML/RARa-and PLZF/RARa-expressing U937 cells were stained with anti-PU.1 and either anti-PML or anti-PLZF antibodies, respectively. Mock-transfected cells were used as controls. In the control cells, the superimposition of anti-PU.1 staining (red fluorochrome) and anti-PML or anti-PLZF staining (green fluorochrome) indicated co-localization of a PU.1 fraction and PML, whereas PLZF is not expressed in those cells (Figures 1e--f) . In cells expressing PML/RARa or PLZF/RARa, superimposition of the anti-PU.1 and anti-PML or anti-PLZF signals revealed that a large fraction of PU.1 co-localized with both PML/ RARa and PLZF/RARa 'microspeckles' (Figure 1e--f ). The treatment with ATRA led to a degradation of the X-RARa with consequent decrease of the co-localization dots (Figure 1e--f) .
These results clearly indicate that X-RARa proteins de-localize a consistent portion of the PU.1 protein, likely resulting in the sequestration of PU.1.
The presence of X-RARa proteins decrease the solubility of PU.1 in U937 cells The disruption of the X-RARa speckles and the resulting microspeckled X-RARa staining pattern are correlated with the decreased association of the fusion proteins with the nuclear matrix compared with their physiological counterparts PML and PLZF.
24,31 --33 Therefore, we investigated whether PU.1 also looses its nuclear matrix association in the presence of X-RARa proteins due to its sequestration. SDS solubilizes whole-cell components, whereas NP-40 leaves nuclear matrix-associated proteins in the insoluble fraction. 34 Thus, we lysed U937 cells expressing the fusion proteins with NP-40-and SDS-based buffers to examine the effects of the fusion proteins on the solubility of PU.1. Similar to previous reports, 35 we found that PU.1 levels diminished in the NP-40-soluble fraction in a time-dependent manner upon the expression of PML/RARa and PLZF/RARa, whereas PU.1 was present at high levels in the NP-40-insoluble fraction (Figure 2a) . In the SDS whole-cell lysate, no changes in PU.1 protein levels were seen in the presence of X-RARa proteins (Figure 2b ). In summary, our data suggest that PU.1 solubility decreases in the presence of X-RARa proteins.
The X-RARa proteins interfere with serine phosphorylation of PU.1 PU.1 activity is regulated by its serine phosphorylation (p-Ser). 36, 37 Specifically, phorbol esters induce phosphorylation-dependent DNA binding of PU.1, which positively correlates with the inhibition of leukemic cell growth. 38 To investigate whether X-RARa proteins can interfere with PU.1 phosphorylation, we assessed the PU.1 phosphorylation status of X-RARa-positive hematopoietic progenitor cells (HPCs) induced to monocytic differentiation. We exposed the PML/RARa-positive NB4 cell line, as well as HL60 cells expressing PLZF/RARa, 28 to VitD 3 and TGF-b. HL60-wt cells were used as a negative control. After VitD 3 and TGF-b treatment the cells expressing X-RARa showed a reduction in CD14 expression compared with the HL60-wt cells (Figure 3a) . Furthermore, PU.1 expression increased upon treatment with VitD 3 /TGF-b in all three cell lines (Figure 3b) . The anti-p-Ser antibody revealed increased phosphorylation only in the HL60-wt cells. In contrast, both NB4 and HL60 PLZF/RARa cells exhibited a reduction in p-Ser of PU.1 (Figure 3b) .
Taken together, these data demonstrate that X-RARa expression is also accompanied by a reduction in PU.1 phosphorylation upon monocytic differentiation, which likely contributes to the induction of the leukemic phenotype.
The presence of X-RARa and AML1/ETO proteins reduces the promoter-binding capacity of PU. 1 The phosphorylation status of PU.1 is important for its transcriptional activity. To assess the influence of X-RARa proteins on the promoter-binding capacity of PU.1, we performed ChIP experiments in U937 cells stably expressing PML/RARa, PLZF/RARa or AML-1/ETO. 10, 9 We performed ChIP/qPCR assays using specific primers for the PU.1 target genes: the proximal region of the PU.1 promoter itself, 39, 40 the IL-18 promoter, 23 the promoter of the monocytic colony-stimulating factor receptor (c-fms) and the FES promoter region 39, 41 (Figure 3c ). As control targeting an irrelevant promoter region we used the PDK4 promoter region (Figure 3d ). The anti-PU.1 antibody is able to precipitate its PU.1 antigen independently of the presence of X-RARa fusion proteins (Figure 3e) .
These results reveal a reduced promoter-binding capacity of PU.1 in the presence of the AML fusion proteins (Figure 3d) .
Next, we analyzed the effects of X-RARa proteins on the transactivation of the c-fms promoter. As positive controls, we used the IL-18 promoter, a well-established PU.1 target promoter in U937 cells, 23 and the AML-1/ETO protein, which displays a reported inhibitory activity towards PU.1.
9 X-RARa proteins reduced the activation of both promoters to an extent similar to that of AML-1/ETO (Figure 4a ). The expression levels of the transgenes were assessed by western blot analysis (Figure 4b ). The activation of these promoters is specifically dependent on PU.1, as shown by the dramatically reduced activity of the promoters when the PU.1-binding sites were mutated (c-fms DPU.1 and IL18 DPU.1) (Figure 4d ). Figure 4c shows a schematic of the used promoters and indicates the deleted PU.1 sites.
Self-regulation of PU.1 is important for the appropriate control of its function; 40 therefore, we analyzed the expression of the PU.1 transcript to assess the effect of X-RARa on the self-regulation of the PU.1 promoter. As shown in Figure 4e , the level of PU.1 transcripts detected by quantitative real-time PCR decreased with increasing time of exposure to the fusion proteins. A subsequent decrease in PU.1 protein expression was confirmed by western blot analysis (Figure 4f) .
In summary, these data indicate that the presence of the X-RARa proteins inhibit the binding of PU.1 to its responsive elements within different target promoters and interfere with the transcriptional activity of PU.1 on the c-fms and IL18 promoters.
In early HPCs, PU.1 overcomes the X-RARa-related block in G/GM-CSF-induced differentiation The function of PU.1 is indispensable for hematopoiesis. 16, 42 Its reduced expression leads to the induction of leukemia, and several PU.1 mutations have been implicated in leukemia. 43 The leukemia-associated protein PML/RARa reduces the levels of PU.1 transcription in vivo. 35 In mouse models, a complete loss of PU.1 or a gradual reduction in PU.1 expression leads to AML. 17, 44 This information prompted us to evaluate how the forced overexpression of PU.1 impacts the expression of PML/RARa or PLZF/RARa in HPCs. To answer this question, PU.1 and X-RARa were retrovirally co-expressed in Sca1 þ /Lin À mHPCs. We used the bicistronic retroviral vectors PINCO and PAULO, which express PML/RARa, PLZF/RARa or PU.1 under the control of an LTR, and express the EGFP (PINCO) or DNGFR (PAULO) transgenes under the control of the CMV promoter (Figure 5a ). Cells double mockinfected with PINCO and PAULO were used as control. On day 7 post-infection, spontaneous and G/GM-CSF-induced differentiation was assessed by examining either morphology or expression of the surface markers Mac-1 and Gr-1 by FACS. Morphological analysis using May --Grü nwald --Giemsa staining showed that the overexpression of PU.1 overcame the differentiation block in X-RARa-positive cells (Figure 5c ). The differentiation of X-RARa positive cells in the presence of PU.1, was confirmed by the restoration of Mac-1 expression to levels comparable with those of controls and the increase of the Gr-1 expression (Figure 5d ). The expression levels of the single transgenes did not differ between cells that expressed the transgenes singly or in combination, suggesting that the effects observed were unlikely to be consequences of differences in expression levels (Figure 5b) . Taken together, our results show that the overexpression of PU.1 in PML/RARa-and PLZF/RARa-positive cells can overcome the fusion protein-mediated differentiation block, likely by restoring a sufficient level of functional PU.1. DISCUSSION PU.1 is a key factor in hematopoiesis and its inactivation contributes to leukemogenesis. Several mechanisms of PU.1 inactivation have been described, such as mutations, 45 --47 competition for co-activators 9 and transcriptional downregulation. 35, 48 The aim of this study was to further elucidate the mechanisms by which X-RARa proteins interfere with the function of PU.1.
Here, we report that X-RARa proteins interact directly with PU.1, leading to its functional inactivation. The inactivation of PU.1 by X-RARa proteins can be attributed mainly to two mechanisms that seem to have the same effect. The first mechanism involves the sequestration and de-localization of at least a portion of PU.1 from the nucleosol to the nuclear matrix. The second mechanism is a result of a decreased serine phosphorylation of PU.1 by the X-RARa. Both mechanisms can lead to reduced transcriptional activity of PU.1 at its target promoters. Sequestration could result in a quantitative reduction in PU.1 binding at its target sequences, whereas reduced serine phosphorylation could reduce the binding affinity of PU.1 to its DNA-consensus at target promoters.
Using an inducible system, we showed here that this reduced PU.1 activity not only results in a diminished activation of its target genes but also causes reduction in PU.1 expression by interrupting the PU.1-specific self-activation loop. 40 As a final consequence, we speculate that the functional inhibition of PU.1 may cause the reduction in PU.1 expression that induces leukemia. On the basis of our findings, we propose that the physical interaction between PU.1 and X-RARa contributes significantly to the inactivation of PU.1, confirming the results of Wang et al. 29 Importantly, in addition to the model proposed by Wang et al., 29 we report a new mechanism. We have demonstrated here that the serine phosphorylation of PU.1, which is critical for its transcriptional function 38, 49, 50 and necessary for its DNA-binding capacity, 38 is strongly reduced by PML/RARa in the NB4 APL cell line and is also associated with the inhibition of VitD 3 -induced monocytic differentiation. Furthermore, expressing PLZF/RARa in HL60 cells also reduces the serine phosphoryltion of PU.1. As PML cooperates with PU.1 by activating PU.1 target genes, PML/RARa may also inhibit PU.1 by inhibiting normal PML function. The C-terminus of PML interacts with PU.1, and PML/RARa functions as a dominant-negative PML, inhibiting this interaction. 19 Similarly to AML-1/ETO, the X-RARa proteins inhibit the transcriptional activation of PU.1 target genes. These data confirm the recently reported relationship between PML/RARa expression and the suppression of the PU.1-mediated activation of the monocytic c-fms, which can be released by exposure to retinoic acid. 39 In keeping with these data, we showed in our ChIP assays that PML/RARa and PLZF/RARa inhibit PU.1 from binding to its target sequences in the IL18, c-fms, FES and the PU.1 promoter, respectively. Oligonucleotide arrays showed that PU.1 itself and several target genes of PU.1, 51 such as the major histocompatibility complex, integrin A2b and the immunoglobulin heavy constant chain, were downregulated by X-RARa (data not shown). 35, 52 Our findings regarding the mechanism by which X-RARa proteins interfere with the function of PU.1 are in agreement with the data of Mü ller et al., 35 who showed that PU.1 is downregulated at the transcriptional and protein levels in cells expressing PML/RARa and PLZF/RARa (Figure 4e--f) . In our experiments, we showed that the use of detergents with differing solubilization properties resulted in different PU.1 protein yields. This difference is probably due to the fact that X-RARa proteins localize PU.1 to the NP-40-insoluble fraction, which contains the nuclear matrix. 34 In fact, our data suggest that the X-RARa proteins, which partially reside within the nuclear matrixassociated fraction, 53,34 may de-localize PU.1 into the nuclear matrix.
The functional inactivation of PU.1 is not restricted to the X-RARa proteins. A similar mechanism was recently described for AML-1/ETO, which does not downregulate PU.1, but competes for the binding site of its co-activator, c-Jun. 9 An increasing level of X-RARa could correlate with progressively decreasing PU.1 function. The gradual reduction of PU.1 to 20% of its normal level and the complete deletion of PU.1 leads to an aggressive, AML-like disease in mice. 16, 17 Here, we show that restoring functional PU.1 by overexpression overcomes the differentiation block in PML/RARa-and PLZF/RARa-positive HPCs.
Taken together, our data indicate that the X-RARa proteins functionally inhibit PU.1 both by physical interaction with PU.1 and inhibition of its post-translational modification. In this work, we showed that the X-RARa proteins have an important role in the inactivation of PU.1, representing a decisive step in the induction of AML.
We suggest that the post-transcriptional modification of a transcription factor, together with its sequestration, may contribute to the leukemic phenotype induced by the previously mentioned fusion proteins. A possible method for elucidating the molecular mechanisms of leukemia is to screen the protein modification states of various key markers specific for differentiation, proliferation and stem-cell status. This approach could detect modifications of specific proteins and enable a better understanding of the crosstalk between pathways involved in the pathogenesis of leukemia.
